Tuesday, October 20, 2015

Eye drug setback hits Shire shares amid Baxalta pursuit

LONDON (Reuters) - Shares in Shire Plc fell 2 percent on Monday after the U.S. Food and Drug Administration (FDA) decided not to approve its most important pipeline medicine for dry eye disease and asked for more information.









No comments:

Post a Comment